Volume 4, Issue 3 (Int J Mol Cell Med 2015)                   Int J Mol Cell Med 2015, 4(3): 143-151 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Naddafi F, Davami F. Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy. Int J Mol Cell Med 2015; 4 (3) :143-151
URL: http://ijmcmed.org/article-1-306-en.html
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
Fatemeh Naddafi1 , Fatemeh Davami 2
1- Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. , f_davami@pasteur.ac.ir
Abstract:   (8945 Views)

CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating CD19- positive lymphomas and autoimmune diseases would rank among the most novel area of research and development in the pharmaceutical industry. Moreover, several anti- CD19 mAbs are currently being tested in various clinical trials and this review provides an overview of the research accomplished so far.

Keywords: Anti-CD19, monoclonal antibodies, B-cell lymphoma, anti-CD19 sFv, blinatumumab
Full-Text [PDF 159 kb]   (3681 Downloads)    
Type of Study: Review | Subject: Medical Pharmacology
Received: 2015/03/7 | Accepted: 2015/05/25 | Published: 2015/07/21
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | International Journal of Molecular and Cellular Medicine (IJMCM)

Designed & Developed by : Yektaweb